18c1220). Availability of data and materials All data generated or analyzed during the present study are included in this published article. Authors’ contributions YZ conceived and designed the study, and wrote the manuscript. migration of gastric malignancy cells by focusing on SOX5. and Epstein-Barr disease infection, alcohol misuse, body mass index and physical activity (17), while the internal factors are manifested in genetic inheritance (18). In the treatment of early gastric malignancy, surgical resection remains the main restorative strategy. During the postoperative period, additional comprehensive treatment actions, such as adjuvant chemotherapy, can be applied. However, the overall end result of gastric malignancy remains unfavorable. In recent years, molecular targeted therapy offers gradually a research focus, and increasing molecular target medicines have been applied in clinical tests. Thus, exploration of fresh molecular markers or focuses on will become helpful for analysis in gastric malignancy. Accumulating S107 studies possess shown that microRNAs can function as oncogenes or tumor suppressor genes by differential manifestation in a variety of tumor cells. Some microRNAs can promote the proliferation, invasion or metastasis of tumor cells in malignant tumors through multiple pathways. For instance, miR-539 is able to inhibit the invasion and migration of osteogenic sarcoma cells by focusing on matrix metalloproteinase-8 (18). In HCC, low manifestation of miR-539 was reported in malignancy cells and cells, and this miRNA was able to induce HCC cell apoptosis by mediating transmission transducer and activator of transcription 3 pathway (11). In the present study, miR-539 was observed to be downregulated in gastric malignancy cells and cell lines. S107 In combination with the findings of a earlier study (13), it is hypothesized that miR-539 functions like S107 a tumor suppressor in gastric malignancy. In the subsequent experiments, the proliferation of MGC803 and SGC7901 cells transfected with miR-539 mimic was found to be significantly decreased. The results of transwell assay indicated that miR-539 advertised the migration of IL22RA2 gastric malignancy cells. Next, the potential target gene of miR-539 was expected by TargetScan and miRanda, and it was observed that SOX5 was a potential target of miR-539, which was then verified by luciferase assay. Compared with Mut SOX5 reporter S107 vector, miR-539 mimic significantly reduced the luciferase activity of WT SOX5 reporter vector. Previous studies possess shown that SOX5 participates in the process of tumor epithelial-mesenchymal transition S107 (EMT). EMT is definitely accompanied by designated changes in cell morphology and behavior, such as in cell proliferation, differentiation, adhesion and migration. In addition, EMT can enhance the migration and invasion properties of malignancy cells, and induce stem cell properties in tumor cells (19,20). Study has also exposed that SOX5 in breast cancer can directly bind to the Twist1 promoter to activate the gene manifestation, while it also settings the ETM process, suggesting that SOX5 participates in the progression of breast tumor by activating the Twist1/ETM axis (21). However, in osteogenic sarcoma, SOX5 promotes cell migration and invasion, which may be achieved by regulating the manifestation of Snail, so as to promote EMT (22). Consistent with the observations of earlier studies investigating SOX5 in additional tumors, the present study suggested that SOX5 was highly indicated in medical instances of gastric malignancy, and that SOX5 overexpression repressed cell proliferation and migration, which was in contrast to the effect of SOX5 silencing. The results of rescue experiments shown that cell proliferation and migration was significantly increased following transfection with miR-539 and SOX5 overexpression vector, implying that miR-539 inhibited the proliferation and migration of gastric malignancy cells by focusing on SOX5. Centered on the research results, it is speculated the inhibitory effect of miR-539 within the proliferation and migration of gastric malignancy cells may be achieved.